Table 4 Clinical-stage development of monotherapies and combinatory therapies with immune checkpoint inhibitors in 2021, according to www.clinicaltrials.gov
From: Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
Target | Drug name | Indication | Status |
|---|---|---|---|
CTLA-4 + PD-1 | Ipilimumab + nivolumab | NSCLC (NCT03351361) (NCT02864251) (NCT02477826) (NCT02869789) (NCT03391869) (NCT04026412) (NCT02998528) (NCT03215706); gastric cancer; GEJ cancer (NCT02872116) (NCT03604991); HNSCC (NCT03700905); metastatic HNSCC (NCT02741570); melanoma (NCT02905266) (NCT02599402) (NCT03068455) (NCT02388906); SCLC (NCT02538666); RCC (NCT03793166) (NCT03873402) (NCT03937219) (NCT03138512) (NCT04513522); esophageal cancer (NCT03143153); sarcoma (NCT04741438); glioblastoma (NCT02017717) (NCT04396860); squamous cell lung cancer (NCT02785952); metastatic urothelial cancer (NCT03036098); metastatic prostate cancer (NCT03879122) | Phase III |
CTLA-4 + PD-1 | Ipilimumab + pembrolizumab | Metastatic NSCLC (NCT03302234); metastatic melanoma (NCT01866319); solid tumors (NCT03755739) | Phase III |
CTLA-4 + PD-1 | Ipilimumab + REGN2810 | NSCLC (NCT03515629) (NCT03409614) | Phase III |
CTLA-4 + PD-L1 | Tremelimumab + durvalumab | Advanced solid tumors (NCT03084471); HNSCC (NCT02369874); NSCLC (NCT02453282); SCLC (NCT03703297); metastatic NSCLC (NCT02542293) (NCT02352948) (NCT03164616); metastatic urothelial cancer (NCT03682068); urothelial cancer (NCT02516241); metastatic HNSCC (NCT02551159); HCC (NCT03298451); squamous cell lung cancer (NCT02154490); RCC (NCT03288532); SCLC (NCT03043872) | Phase III |
PD-1 + LAG-3 | Nivolumab + relatlimab | Metastatic melanoma (NCT03470922) | Phase III |
PD-1 + LAG-3 + B7-H3 | MGD013 + enoblituzumab | Gastric cancer; GEJ cancer (NCT04082364), metastatic HNSCC (NCT04129320) | Phase III |
PD-1 + TIGIT | Tislelizumab + BGB-A1217 | NSCLC (NCT04746924) | Phase III |
PD-1 + TIGIT | Zimberelimab + AB154 | Metastatic NSCLC (NCT04736173) | Phase III |
PD-1 + B7-H3 | MGA012 + enoblituzumab | Metastatic HNSCC (NCT04129320) | Phase III |
PD-L1 + TIGIT | Atezolizumab + tiragolumab | NSCLC (NCT04294810) (NCT04513925); SCLC (NCT04256421) (NCT04665856); esophageal squamous cell carcinoma (NCT04540211) (NCT04543617); | Phase III |
LAG-3 + PD-1 | Relatlimab + nivolumab | Multiple solid tumors (NCT01968109); CRC (NCT03642067); metastatic soft-tissue sarcoma (NCT04095208); HNSCC (NCT04080804); NSCLC (NCT04205552) (NCT02750514); RCC (NCT02996110); gastric cancer (NCT02935634); metastatic melanoma (NCT04552223) (NCT03743766) (NCT03724968); solid tumors (NCT03607890); HCC (NCT04567615); metastatic basal cell carcinoma (NCT03521830); HNSCC (NCT04326257); metastatic NSCLC (NCT04623775); metastatic CRC (NCT03867799); GEJ adenocarcinoma (NCT03704077) (NCT03662659) (NCT03610711) (NCT04062656); advanced cancers (NCT03459222) (NCT02488759); metastatic ovarian cancer (NCT046111269); melanoma (NCT02519322); multiple myeloma (NCT04150965) | Phase II |
LAG-3 + PD-1 | BI-754111 + BI-754091 | Metastatic solid tumors (NCT03697304) | Phase II |
LAG-3 + PD-1 | REGN3767 + cemiplimab | Breast cancer (NCT01042379); metastatic solid tumors (NCT04706715) | Phase II |
LAG-3 + PD-1 | LAG525 + spartalizumab | TNBC (NCT03499899); advanced malignancies (NCT03365791) (NCT02460224); melanoma (NCT03484923) | Phase II |
LAG-3 + PD-1 + TIM-3 | INCAGN02385 + INCMGA00012 + INCAGN02390 | Advanced malignancies (NCT04370704) | Phase II |
LAG-3 + PD-1 | MK-4280 + pembrolizumab | Hodgkin lymphoma; non-Hodgkin lymphoma (NCT03598608); advanced NSCLC (NCT03516981) | Phase II |
TIM-3 | MBG453 | Myelodysplastic syndromes; chronic myelomonocytic leukemia (NCT04266301) | Phase III |
TIM-3 | MBG453 | AML (NCT04150029) (NCT04623216); advanced solid tumors (NCT02608268); myelofibrosis (NCT04097821) | Phase II |
TIM-3 + PD-1 | BMS-986258 + nivolumab | Solid tumors (NCT03446040) | Phase II |
TIM-3 + PD-1 | BGB-A425 + tislelizumab | Solid tumors (NCT03744468) | Phase II |
TIM-3 + PD-1 | TSR-022 + TSR-042 | Liver cancer (NCT03680508); melanoma (NCT04139902) | Phase II |
TIGIT + PD-L1 | Tiragolumab + atezolizumab | Cervical cancer (NCT04300647); gastric adenocarcinoma; GEJ adenocarcinoma; esophageal carcinoma (NCT03281369); urothelial carcinoma (NCT03869190); pancreatic adenocarcinoma (NCT03193190); NSCLC (NCT03563716); metastatic NSCLC (NCT04619797); metastatic HNSCC (NCT04665843); SCLC (NCT04308785); HNSCC (NCT03708224); liver cancer (NCT04524871) | Phase II |
TIGIT + PD-1 | AB154 + zimberelimab | NSCLC (NCT04262856) | Phase II |
TIGIT | BMS-986207 | Multiple myeloma (NCT04150965) | Phase II |
TIGIT + PD-1 | BMS-986207 + nivolumab | Solid tumors (NCT02913313) (NCT04570839) | Phase II |
PVRIG + PD-1 | COM701 + nivolumab | Advanced solid tumors (NCT03667716) (NCT04570839) | Phase I |
KIR2DL1 + KIR2DL2 + KIR2DL3 | Lirilumab | AML (NCT01687387); chronic lymphocytic leukemia (NCT02481297); refractory AML (NCT02399917) | Phase II |
KIR2DL1 + KIR2DL2 + KIR2DL3 + PD-1 | Lirilumab + nivolumab | HNSCC (NCT03341936); metastatic malignancies (NCT03347123); multiple myeloma (NCT01592370); refractory tumors (NCT02813135) | Phase II |
KIR2DL1 + KIR2DL2 + KIR2DL3 + PD-1 + CTLA-4 | Lirilumab + nivolumab + ipilimumab | Advanced solid tumors (NCT01714739) | Phase II |
KIR3DL2 | IPH4102 | Advanced T cell lymphoma (NCT03902184). | Phase II |
NKG2A | Monalizumab | Metastatic HNSCC (NCT04590963) | Phase III |
NKG2A | Monalizumab | Metastatic HNSCC (NCT02643550) (NCT03088059); breast cancer (NCT04307329); chronic lymphoid leukemia (NCT02557516) | Phase II |
NKG2A + PD-L1 | Monalizumab + durvalumab | CRC (NCT04145193); solid tumors (NCT02671435); NSCLC (NCT03822351) (NCT038223519) (NCT03833440) | Phase II |
CD200 | Samalizumab | AML (NCT03013998), multiple myeloma (NCT00648739) | Phase II |
CD47 | Magrolimab | Myelodysplastic syndrome (NCT04313881); AML (NCT04778397) | Phase III |
CD47 + PD-L1 | Magrolimab + atezolizumab | Metastatic urothelial carcinoma (NCT03869190) | Phase II |
CD47 | Magrolimab | Solid tumors (NCT02953782); refractory B-cell non-Hodgkin lymphoma (NCT02953509); myeloid malignancies (NCT04778410) | Phase II |
CD47 | RRX-001 | SCLC (NCT03699956) | Phase III |
CD47 | RRX-001 | Solid tumors (NCT02489903); metastatic CRC (NCT02096354) | Phase II |
BTLA | JS004 | Advanced solid tumors (NCT04278859) | Phase I |
BTLA | TAB004 | Advanced solid malignancies (NCT04137900) | Phase I |
VISTA | JNJ-61610588 | Advanced solid tumors (NCT02671955) | Phase I |
VISTA + PD-L1 | CA170 | Advanced solid tumors and lymphomas (NCT02812875) | Phase I |
B7-H3 | Enoblituzumab | Metastatic HNSCC (NCT04129320) | Phase III |
B7-H3 | Enoblituzumab | Prostate cancer (NCT02923180) | Phase II |
B7-H3 | 131I-omburtamab | Neuroblastoma; central nervous system metastases; leptomeningeal metastases (NCT03275402) | Phase III |
B7-H3 | 177Lu-DTPA-omburtamab | Medulloblastoma (NCT04167618); solid tumors (NCT04315246) | Phase II |
B7-H3 | DS-7300a | Advanced solid tumors (NCT04145622) | Phase II |
B7-H3 + PD-1 | MGC018 + MGC012 | Advanced solid tumors (NCT03729596) | Phase II |